Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline

Cancer statistics, 2022

(2022) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local–Regionally Advanced Head and Neck Squamous Cell Carcinoma

(2022) Trisha M. Wise-Draper et al.   CLINICAL CANCER RESEARCH

Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

(2022) Christine H. Chung et al.   CLINICAL CANCER RESEARCH

Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score

(2022) Barbara Burtness et al.   JOURNAL OF CLINICAL ONCOLOGY

Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma

(2022) Robert I Haddad et al.   Journal for ImmunoTherapy of Cancer

Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)

(2021) Feng-Hua Wang et al.   JOURNAL OF CLINICAL ONCOLOGY

Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline

(2021) Yu-Pei Chen et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-L1 as a biomarker of response to immune-checkpoint inhibitors

(2021) Deborah Blythe Doroshow et al.   Nature Reviews Clinical Oncology

I’m Not Putting on that Floral Gown: Enforcement and Resistance of Gender Expectations for Transgender People with Cancer

(2021) Ash B. Alpert et al.   PATIENT EDUCATION AND COUNSELING

Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study

(2021) Christine H. Chung et al.   Cancers

Radiotherapy and Immunotherapy for Head and Neck Cancer: Current Evidence and Challenges

(2021) Jack M. Qian et al.   Frontiers in Oncology

Management of Salivary Gland Malignancy: ASCO Guideline

(2021) Jessica L. Geiger et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial

(2021) Assuntina G Sacco et al.   LANCET ONCOLOGY

Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

(2021) Nancy Y Lee et al.   LANCET ONCOLOGY

LBA35 Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Randomized phase III GORTEC-REACH trial

(2021) J. Bourhis et al.   ANNALS OF ONCOLOGY

Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial

(2021) Yunpeng Yang et al.   LANCET ONCOLOGY

Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial

(2021) Hai-Qiang Mai et al.   NATURE MEDICINE

Anti–PD-1 and Anti–PD-L1 in Head and Neck Cancer: A Network Meta-Analysis

(2021) Andrea Botticelli et al.   Frontiers in Immunology

Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States

(2020) Robert Haddad et al.   JOURNAL OF MEDICAL ECONOMICS

Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study

(2020) R.L. Ferris et al.   ANNALS OF ONCOLOGY

Diagnosis and Management of Squamous Cell Carcinoma of Unknown Primary in the Head and Neck: ASCO Guideline

(2020) Ellie Maghami et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412

(2020) Jean-Pascal Machiels et al.   Future Oncology

Two‐year follow‐up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck ( CheckMate 141)

(2020) Chia‐Jui Yen et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Cancer Disparities and Health Equity: A Policy Statement From the American Society of Clinical Oncology

(2020) Manali I. Patel et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma

(2020) Sean McBride et al.   JOURNAL OF CLINICAL ONCOLOGY

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

(2020) Aurélien Marabelle et al.   LANCET ONCOLOGY

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

(2020) Roy S. Herbst et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer

(2020) Kenneth Emancipator et al.   MODERN PATHOLOGY

Molecular phenotypes of circulating tumor cells and efficacy of nivolumab treatment in patients with head and neck squamous cell carcinoma

(2020) Hiroe Tada et al.   Scientific Reports

Age and Mutations as Predictors of the Response to Immunotherapy in Head and Neck Squamous Cell Cancer

(2020) Yueming Zhang et al.   Frontiers in Cell and Developmental Biology

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

(2019) Robert M. Samstein et al.   NATURE GENETICS

Management of the Neck in Squamous Cell Carcinoma of the Oral Cavity and Oropharynx: ASCO Clinical Practice Guideline

(2019) Shlomo A. Koyfman et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort

(2019) Neil H. Segal et al.   EUROPEAN JOURNAL OF CANCER

Safety of radiotherapy with concurrent and adjuvant MEDI4736 (durvalumab) in patients with locoregionally advanced head and neck cancer with a contraindication to cisplatin: NRG-HN004.

(2019) Loren K. Mell et al.   JOURNAL OF CLINICAL ONCOLOGY

A Phase I/II Open‐Label Study of Nivolumab in Previously Treated Advanced or Recurrent Nasopharyngeal Carcinoma and Other Solid Tumors

(2019) Yuxiang Ma et al.   ONCOLOGIST

Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial

(2019) Robert Haddad et al.   CANCER

Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use

(2019) Robert L. Ferris et al.   CLINICAL CANCER RESEARCH

Radiotherapy with Concurrent and Adjuvant Pembrolizumab in Patients with P16-Positive Locoregionally Advanced Head and Neck Cancer: KEYCHAIN Trial Lead-In Results

(2019) A.G. Sacco et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Nivolumab versus investigator’s choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age

(2019) Nabil F. Saba et al.   ORAL ONCOLOGY

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

(2019) Aurelien Marabelle et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

(2019) Barbara Burtness et al.   LANCET

HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma

(2019) Jian Wang et al.   Scientific Reports

Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma

(2018) Roger B. Cohen et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)

(2018) Brigette B.Y. Ma et al.   JOURNAL OF CLINICAL ONCOLOGY

CheckMate 141: 1‐Year Update and Subgroup Analysis of Nivolumab as First‐Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer

(2018) Maura L. Gillison et al.   ONCOLOGIST

Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression

(2018) Robert L. Ferris et al.   ORAL ONCOLOGY

Human Papillomavirus Testing in Head and Neck Carcinomas: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists Guideline

(2018) Carole Fakhry et al.   JOURNAL OF CLINICAL ONCOLOGY

1117TiPIMvoke010: Randomized phase III study of atezolizumab (atezo) as adjuvant monotherapy after definitive therapy of squamous cell carcinoma of the head and neck (SCCHN)

(2018) R Haddad et al.   ANNALS OF ONCOLOGY

1123TiPA randomized phase II study of cisplatin plus radiotherapy versus durvalumab plus radiotherapy followed by adjuvant durvalumab versus durvalumab plus radiotherapy followed by adjuvant tremelimumab and durvalumab in intermediate risk, HPV-positive, locoregionally advanced oropharyngeal squamous cell cancer (LA-OSCC) (Canadian Cancer Trials Group HN.9)

(2018) A Spreafico et al.   ANNALS OF ONCOLOGY

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic

(2018) T A Chan et al.   ANNALS OF ONCOLOGY

Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy

(2018) Dan P. Zandberg et al.   EUROPEAN JOURNAL OF CANCER

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

(2018) Ezra E W Cohen et al.   LANCET

Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC

(2018) Lillian L. Siu et al.   JAMA Oncology

Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline

(2017) Timothy Gilligan et al.   JOURNAL OF CLINICAL ONCOLOGY

American Society of Clinical Oncology Position Statement: Strategies for Reducing Cancer Health Disparities Among Sexual and Gender Minority Populations

(2017) Jennifer Griggs et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study

(2017) Joshua Bauml et al.   JOURNAL OF CLINICAL ONCOLOGY

Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update

(2017) Betty R. Ferrell et al.   JOURNAL OF CLINICAL ONCOLOGY

Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

(2017) Kathryn R Tringale et al.   JNCI-Journal of the National Cancer Institute

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

(2017) Padmanee Sharma et al.   LANCET ONCOLOGY

Cost-effectiveness of nivolumab for recurrent or metastatic head and neck cancer☆

(2017) Matthew C. Ward et al.   ORAL ONCOLOGY

A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator’s choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141

(2017) Naomi Kiyota et al.   ORAL ONCOLOGY

Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

(2017) Kathryn R Tringale et al.   JNCI-Journal of the National Cancer Institute

Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received

(2016) Lowell E. Schnipper et al.   JOURNAL OF CLINICAL ONCOLOGY

Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort

(2016) Laura Q.M. Chow et al.   JOURNAL OF CLINICAL ONCOLOGY

Programmed death ligand-1 expression is associated with poor disease free survival in salivary gland carcinomas

(2016) Takashi Mukaigawa et al.   JOURNAL OF SURGICAL ONCOLOGY

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

(2016) Robert L. Ferris et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options

(2015) Lowell E. Schnipper et al.   JOURNAL OF CLINICAL ONCOLOGY

Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia

(2013) Stacie B. Dusetzina et al.   JOURNAL OF CLINICAL ONCOLOGY

GRADE guidelines: 3. Rating the quality of evidence

(2011) Howard Balshem et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Building better guidelines with BRIDGE-Wiz: development and evaluation of a software assistant to promote clarity, transparency, and implementability

(2011) Richard N Shiffman et al.   JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION

Patient and Plan Characteristics Affecting Abandonment of Oral Oncolytic Prescriptions

(2011) Sonya Blesser Streeter et al.   Journal of Oncology Practice

American Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care

(2009) Neal J. Meropol et al.   JOURNAL OF CLINICAL ONCOLOGY